VEGFA and interstitial lung disease: Furthermore, the nintedanib, a tyrosine kinase inhibitor which targets PDGF, fibroblast growth factor and vascular endothelial growth factor (VEGF), has recently been approved for the treatment of SSc-ILD [5].